non-alcoholic steatohepataitis (nash) pipeline analysis
TRANSCRIPT
IQ4I Research & Consultancy Pvt. Ltd. Page 1
Nonalcoholic steatohepatitis (NASH) Pipeline Analysis
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive
insights on the various drugs being developed for the treatment of NASH. The report covers
all the drugs that are in various phases of development (Discovery, Preclinical & Clinical).
The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small
molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based
therapeutics, but excludes symptom relief drugs, generic combinations and supplemental
drugs. The report also covers some of the hot targets in research for NASH treatments and
NASH related biomarkers.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual
researchers, Investors, Medical technology companies, Service providers and other
associated stake holders to identify and analyze the available licensing/collaborative
commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The
report also provides strategic insights on some of the molecules that are yet to be launched
in the next few years. Some of the key sections covered in the report are given below:
Epidemiology
o In this section, epidemiology of NASH is reviewed to understand potential
significance and impact of the disease.
o Global & US prevalence rates.
Hot Targets, Mechanisms & Therapies
o In this section, various NASH associated targets, mechanism and upcoming
therapies are discussed. Also, covers novel targets in early research for NASH
along with disease progression biomarkers associated with NASH (Inflammatory,
apoptosis, fibrosis).
Market analysis
o In market analysis section, global NASH drugs market is indicated along with the
estimated Peak sales ($) of leading clinical stage drugs forecasted from 2019-
2025.
o Forecasting model for NASH market.
o NASH market dynamics
o NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept,
Aramchol-Galmed,
o GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-
Avolynt, IVA 337- Inventiva Pharma, GFT505-Genfit)
IQ4I Research & Consultancy Pvt. Ltd. Page 2
Nonalcoholic steatohepatitis (NASH) Pipeline Analysis
o NASH related deals analysis with financials (upfront, milestones and royalties)
o Funding scenario in NASH market
Pipeline Analysis
o Pipeline analysis was carried to get deeper insights on various treatment
modalities in discovery, preclinical & development section, pipelines from major
companies were identified and Potential targets were reported along with
Mechanism of action, Current development status & nature of molecule. Pipeline
analysis by developmental stage (Discovery to Clinical development)
o Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNA-therapeutics pipeline analysis
Recombinant protein pipeline analysis
o Pipeline analysis by leading players & Target analysis
o Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)
Key Players Analysis
o The key player’s analysis section provides an in-depth understanding of various
companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines
with development phase as well as understanding partnering strategies such as
deals entered by the company.
o Global key players overview
o Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
o Global key players deals (Collaborations, Licensing, Service agreements, grants,
funds)